Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Ali J. Satvat is Director at Coherus Oncology. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 10, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
As of the latest filing on , Ali J. Satvat reported holding 30,000 shares of Coherus Oncology (CHRS), worth about $15K at the last close of $1 (Nov 16, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Coherus Oncology CHRS | 30,000 | 30K direct | $1 | $15K | Jun 5, 2026 |
Is this Ali J. Satvat’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Coherus OncologyCHRS
2 disclosures · Jun 2026
Jun 5, 202630Kdisclosed Jun 10
DetailsOfficial recordJun 5, 202660Kdisclosed Jun 10
DetailsOfficial recordOn the latest SEC Form 4, dated Jun 5, 2026, Ali J. Satvat reported holding 30,000 shares of Coherus Oncology (CHRS). At the last close of $1 on Nov 16, 2026, that is about $15K. This is the stake disclosed in filings, not a net worth.